A paradigm shift has been brought to cancer treatment with the approval of a variety of new drugs in diverse cancer types. These drugs include regimens of targeted therapy such as tyrosine kinase inhibitors, monoclonal antibodies, and angiogenesis inhibitors, and immunotherapy involving immune checkpoint inhibitors, for which although remarkable success in improving cancer mortality has been validated in a great number of clinical trials, severe or fatal adverse drug reactions have also been reported in a significant number of patents.
To achieve the optimal treatment and management of cancer patients, it is crucial to prevent, identify, and resolve adverse drug reactions associated with the use of antineoplastics through understanding the mechanisms underlying adverse drug reactions and hypersensitivity, and determining algorithms and biomarkers predictive of these adverse events.
The main goal of this Research Topic is to provide evidence-based approaches to consolidating the knowledge of the assessment, mechanisms, and management of adverse drug reactions associated with cancer treatments. Suitable themes for articles include, but are not limited to:
I. Clinical epidemiology on adverse events in clinical trials and real-world evidence.
II. Diagnosis and assessment of adverse drug reactions in patients with cancer.
III. Management and prognosis of cancer patients with adverse drug reactions.
IV. Mechanisms of hypersensitivity and adverse drug reactions in cancer.
V. Immune-related adverse events following cancer immunotherapy.
VI. Cancer treatments in patients with allergic, immunology-related, and rheumatic diseases or immunocompromised conditions due to viral infections.
VII. Management of allergies in cancer patients during the COVID 19 pandemic
All article types accepted by Frontiers in Allergy are welcome.
A paradigm shift has been brought to cancer treatment with the approval of a variety of new drugs in diverse cancer types. These drugs include regimens of targeted therapy such as tyrosine kinase inhibitors, monoclonal antibodies, and angiogenesis inhibitors, and immunotherapy involving immune checkpoint inhibitors, for which although remarkable success in improving cancer mortality has been validated in a great number of clinical trials, severe or fatal adverse drug reactions have also been reported in a significant number of patents.
To achieve the optimal treatment and management of cancer patients, it is crucial to prevent, identify, and resolve adverse drug reactions associated with the use of antineoplastics through understanding the mechanisms underlying adverse drug reactions and hypersensitivity, and determining algorithms and biomarkers predictive of these adverse events.
The main goal of this Research Topic is to provide evidence-based approaches to consolidating the knowledge of the assessment, mechanisms, and management of adverse drug reactions associated with cancer treatments. Suitable themes for articles include, but are not limited to:
I. Clinical epidemiology on adverse events in clinical trials and real-world evidence.
II. Diagnosis and assessment of adverse drug reactions in patients with cancer.
III. Management and prognosis of cancer patients with adverse drug reactions.
IV. Mechanisms of hypersensitivity and adverse drug reactions in cancer.
V. Immune-related adverse events following cancer immunotherapy.
VI. Cancer treatments in patients with allergic, immunology-related, and rheumatic diseases or immunocompromised conditions due to viral infections.
VII. Management of allergies in cancer patients during the COVID 19 pandemic
All article types accepted by Frontiers in Allergy are welcome.
